Utku Yeliz, Dehan Elinor, Ouerfelli Ouathek, Piano Fabio, Zuckermann Ronald N, Pagano Michele, Kirshenbaum Kent
Department of Chemistry, New York University, New York, NY 10003, USA.
Mol Biosyst. 2006 Jun;2(6-7):312-7. doi: 10.1039/b603229j. Epub 2006 May 17.
RNA interference (RNAi) techniques hold forth great promise for therapeutic silencing of deleterious genes. However, clinical applications of RNAi require the development of safe and efficient methods for intracellular delivery of small interfering RNA (siRNA) oligonucleotides specific to targeted genes. We describe the use of a lipitoid, a cationic oligopeptoid-phospholipid conjugate, for non-viral transfection of synthetic siRNA oligos in cell culture. This peptidomimetic delivery vehicle allows for efficient siRNA transfection in a variety of human cell lines with negligible toxicity and promotes extensive downregulation of the targeted genes at both the protein and the mRNA level. We compare the lipitoid reagent to a standard commercial transfection reagent. The lipitoid is highly efficient even in primary IMR-90 human lung fibroblasts in which other commercial reagents are typically ineffective.
RNA干扰(RNAi)技术在有害基因的治疗性沉默方面前景广阔。然而,RNAi的临床应用需要开发安全有效的方法,将针对目标基因的小干扰RNA(siRNA)寡核苷酸进行细胞内递送。我们描述了一种类脂质(一种阳离子寡肽类磷脂共轭物)在细胞培养中用于合成siRNA寡核苷酸的非病毒转染。这种拟肽递送载体能够在多种人类细胞系中高效转染siRNA,毒性可忽略不计,并在蛋白质和mRNA水平上促进目标基因的广泛下调。我们将类脂质试剂与标准商业转染试剂进行了比较。即使在原代IMR - 90人肺成纤维细胞中,类脂质也具有很高的效率,而其他商业试剂在这些细胞中通常无效。